Australia's CSL to buy Talecris for $3.1 bln

SYDNEY, Aug 13 (Reuters) - Australia's CSL Ltd (CSL.AX), the world's top maker of plasma products, has agreed to buy Talecris Biotherapeutics Holdings Corp, a plasma therapeutics business, for A$3.48 billion ($3.1 billion), CSL said in a statement on Wednesday.

CSL plans to raise $1.5 billion through an institutional share placement to part-fund the deal. ($1=A$1.15) (Reporting by Denny Thomas;) ((denny.thomas@reuters.com; +61 2 9373 1812; Reuters Messaging: denny.thomas.reuters.com@reuters.net))